Neoantigen × AI
Daily research signal
40Brief

mRNA-LNP vaccines outperform plasmid DNA for hepatocellular carcinoma

Preclinical studies highlight critical trade-offs in neoantigen vaccine delivery: while mRNA-LNP formulations show superior immunogenicity and therapeutic efficacy in hepatocellular carcinoma models, plasmid DNA electroporation risks sequestering effector T cells at the injection site rather than directing them to tumors.PubMedPubMed

1new story1 in context
AI / Methods2 days agoNew

A novel bivalent neoantigen vaccine based on mRNA-loaded lipid nanoparticles eradicates hepatocellular carcinoma in mice.

Researchers developed a bivalent mRNA-LNP vaccine targeting AFP and GPC3 neoantigens for hepatocellular carcinoma (HCC). Using spleen-homing CL15H6 LNPs, the formulation achieved superior antigen presentation and co-stimulatory molecule expression on splenic dendritic cells compared to clinical standards. In mouse models, two doses provided complete prophylactic protection against HCC challenge, demonstrating high biosafety and potent cytotoxic T lymphocyte responses.

europepmc · 2 days ago · Younis MA, Sato Y, Elewa YHA, Harashima H.

01

Relevant work from earlier we're still surfacing — not today's news.